

Estimation of the risk of conversion of mild cognitive impairment of Alzheimer type to Alzheimer's disease in a south Brazilian population-based elderly cohort: the PALA study

Cláudia Godinho,^{1,2} Ana Luiza Camozzato,^{1,4} Diego Onyszko¹ and Márcia Lorena Chaves^{1,2,3}

¹Dementia Clinic, Neurology Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil

²UFRGS School of Medicine, Porto Alegre, Brazil

³Internal Medicine Department, UFRGS School of Medicine, Porto Alegre, Brazil

⁴Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, Brazil

ABSTRACT

Background: Higher mild cognitive impairment (MCI) prognostic variability has been related to sample characteristics (community-based or specialized clinic) and to diverse operationalization criteria. The aim of the study was to evaluate the trajectory of MCI of Alzheimer type in a population-based elderly cohort in Southern Brazil. We also estimated the risk for the development of probable Alzheimer's disease (AD) in comparison with healthy subjects.

Methods: Data were derived from a population-based cohort (the PALA study). MCI outcomes were sub-classified into three categories: conversion, stabilization, and reconversion. The risk of progression to dementia was compared between MCI and normal participants. The analysis was based on 21 MCI subjects and 220 cognitively intact participants (N = 241).

Results: Of the 21 MCI subjects, 38% developed dementia, 24% remained stable and 38% improved. The MCI annual conversion rate to AD was 8.5%. MCI was associated with significantly higher risk of conversion to AD (HR = 49.83, p = 0.004), after adjustment for age, education, sex and Mini-Mental State Examination score.

Conclusions: Independent of the heterogeneity of the outcomes, MCI of the Alzheimer type participants showed significantly higher risk of developing probable AD, demonstrating the impact of the use of these MCI criteria that emphasize long-term episodic memory impairment.

Key words: mild cognitive impairment, mild cognitive impairment of Alzheimer type, conversion rate, prodromal AD, Alzheimer's disease

Introduction

The concept of mild cognitive impairment (MCI) is important for the identification of earlier phases of dementia. At first, MCI was considered a transitional state between normal aging and dementia with high prognostic variability (Petersen *et al.*, 1997). The studies that evaluated MCI trajectories – i.e. rates of conversion – showed that some patients remained cognitively stable within the observation period (Wolf *et al.*, 1998; Ganguli *et al.*, 2011), a significant proportion improved (Larrieu *et al.*, 2002; Matthews *et al.*, 2008; Ganguli *et al.*,

2011) and others converted to dementia (Petersen *et al.*, 1997; Jack *et al.*, 2004; Schmidtke and Hermeneit, 2008). This variability has been related to the sample characteristics (community-based or specialized clinic) and to MCI definitions.

There are several MCI criteria which have changed over the time. The original MCI Mayo Clinic criteria emphasized memory deficits and complaints (Petersen *et al.*, 1997) and the subsequent revised criteria were expanded to include other cognitive domains (Winblad *et al.*, 2004). Other MCI definitions did not require subjective memory complaints or specific objective memory deficit (Bozoki *et al.*, 2001; Devanand *et al.*, 2007). More recently, new MCI criteria have emphasized specific impairment of episodic memory characteristic of amnesic syndrome of hippocampal type. This approach assumed the

Correspondence should be addressed to: Márcia L. F. Chaves, Rua Ramiro Barcelos, 2350/ sala 2040, 90035-091, Porto Alegre, RS, Brasil. Phone: +55 51 2101.8520; Fax: +55 51 2101.8001. Email: mchaves@hcpa.ufrgs.br. Received 28 Feb 2011; revision requested 16 May 2011; revised version received 5 Sep 2011; accepted 17 Sep 2011. First published online 17 November 2011.

concept of MCI as prodromal Alzheimer's disease (AD) or MCI of Alzheimer type (Dubois and Albert, 2004). In the same way, the 2007 research criteria for probable AD proposed a change in NINCDS-ADRDA criteria for AD requiring the presence of early and significant episodic memory impairment associated with structural and functional neuroimaging changes and abnormal cerebrospinal fluid (CSF) biomarkers (Dubois *et al.*, 2007). Functional impairment was not needed to fulfill these criteria. Therefore, the MCI concept was incorporated in this new proposal.

The impact of different definitions on observed variability can be exemplified by rates of progression to dementia. Higher values were observed with definitions that highlighted memory deficit, such as the original amnesic criteria (Petersen *et al.*, 1997; Larrieu *et al.*, 2002; Ganguli *et al.*, 2011), the amnesic multiple domain MCI subtypes (Petersen *et al.*, 2001; Ganguli *et al.*, 2011) and the MCI amnesic syndrome of the hippocampal type (Sarazin *et al.*, 2007). Inversely, higher rates to reversion to normal cognition were observed in subjects with nonamnesic MCI (Palmer *et al.*, 2002; Ganguli *et al.*, 2011). When the number of cognitive domains is taken into account, patients with one single domain impaired were at higher risk of reverting to normal cognition (Manly *et al.*, 2008; Ganguli *et al.*, 2011).

Another source of variability is the study setting. Rates of progression from MCI to dementia were consistently higher in specialty clinic than in community settings (Bruscoli and Lovestone, 2004; Hansson *et al.*, 2006; Mitchel and Shiri-Feshki, 2009). Length of follow-up in longitudinal studies was another factor that might explain the heterogeneity of MCI outcomes, however little effect of this variable on annual conversion rates was reported in a systematic review (Bruscoli and Lovestone, 2004).

Annual conversion rates to dementia in people with mild cognitive impairment according to different operational criteria and settings varied from 1.6% to 28% (Bruscoli and Lovestone, 2004; Jack *et al.*, 2004; Schmidtke and Hermeneit, 2008; Artero *et al.*, 2009; Mitchel and Shiri-Feshki, 2009). Overall, the annual conversion rate to AD and dementia was approximately 10% (Bruscoli and Lovestone, 2004; Mitchell and Shiri-Feshki, 2009). However, the majority of population-based studies showed significant proportions of individuals remaining cognitively stable (ranging from 5.4% to 92%) (Larrieu *et al.*, 2002; Mitchel and Shiri-Feshki, 2009; Ganguli *et al.*, 2011) or even reverting to normal cognition (6–53%) (Larrieu *et al.*, 2002; Matthews *et al.*, 2008; Mitchel and Shiri-Feshki, 2009; Ganguli *et al.*, 2011).

Besides rate of progression and its variability, when the risk of developing dementia was compared in MCI and cognitively normal individuals, MCI subjects showed significantly higher risk (Bruscoli and Lovestone, 2004; Matthews *et al.*, 2008; Palmer *et al.*, 2008; Ganguli *et al.*, 2011). The pooled relative risk of MCI progression was 8.9 for AD when comparing with healthy elderly individuals in a meta-analysis (Mitchell and Shiri-Feshki, 2009). The MCI relative risk of conversion to AD varied from 2.77 (Ishikawa *et al.*, 2006) to 63.49 (Dickerson *et al.*, 2007).

Around 24 million people have dementia worldwide. Of those with dementia, 60% live in developing countries, with this number estimated to rise to 71% by 2040 (Ferri *et al.*, 2005). Considering the close relation of MCI and AD, epidemiologic studies about MCI and its longitudinal course should be carried out in these world areas. Nevertheless, there are few studies concerning this issue in these regions. One study carried out in Brazil showed an MCI incidence rate similar to the rates found in developed areas of the world (Chaves *et al.*, 2009a). MCI amnesic prevalence in India was similar to those observed in developed countries and that of the multiple domain type was lower (Das *et al.*, 2007). Chinese MCI subjects showed lower conversion rates to both dementia of Alzheimer type and vascular dementia when compared with American MCI subjects (Huang *et al.*, 2005).

The aim of the study was to evaluate the trajectory of MCI of Alzheimer type in a population-based elderly cohort in southern Brazil. We also estimated the risk for development of probable AD in comparison to healthy subjects.

Methods

Data were derived from an ongoing cohort study known as the PALA (Porto Alegre Longitudinal Aging) study, originally designed to evaluate healthy aging and dementia (Chaves *et al.*, 2009b). At baseline, there were 345 community-dwelling subjects aged 60 years or more, who were healthy and cognitively intact. Those participants who fulfilled criteria for the healthy aging study and consented to participate were evaluated with a detailed clinical interview composed of demographica, clinical and social variables. The Montgomery-Åsberg Depression Rating Scale (MADRS), the Self-Reported Questionnaire – WHO (SRQ), the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria for major depression, the Mini-Mental State Examination (MMSE) and the Clinical Dementia Rating (CDR) were also applied. Additionally,

independence for daily living activities was assessed with the Activities of Daily Living (ADL) scale. A detailed study design has already been published (Chaves *et al.*, 2009b).

Of these 345 baseline subjects, 18 went on to develop dementia; 22 developed MCI, 245 remained without cognitive impairment and 60 dropped-out (54 were not traceable and 6 refused to participate) at follow-up after a maximum of 10 years. Participants for the current study are the above 22 MCI incident cases and the 245 subjects who did not have cognitive impairment established at that time. These 267 subjects were additionally followed for the maximum of 70 months to evaluate the MCI outcomes and the relative risk of developing dementia. Of the 22 MCI subjects, one dropped out (through refusal to participate). Of the 245 participants without cognitive impairment, five declined to participate and 20 were not traceable. At least one additional follow-up assessment to ascertain diagnosis was completed for the 241 participants. All baseline instruments were re-applied at each follow-up assessment and participants underwent a standardized neuropsychological and a neurological evaluation. They were interviewed in their home environment by trained medical students and physicians.

The diagnostic criteria for “MCI of Alzheimer-type” (Dubois and Albert, 2004) were applied as follows: (1) memory complaints reported by the patient or the family; (2) progressive onset; (3) normal or mildly impaired complex activities of daily living; (4) amnesic syndrome of the “hippocampal type” defined by very poor free recall despite adequate (and controlled) encoding; decreased total recall because of insufficient effect of cueing or impaired recognition; numerous intrusions; (5) persistence of memory changes at a subsequent assessment; (6) absence of the fully developed syndrome of dementia; and (7) exclusion of other disorders that may cause MCI, with adequate tests, including neuroimaging. The MCI diagnosis was determined by a senior researcher (a clinician specialized in geriatric psychiatry/behavioral neurology) using the above criteria.

The diagnosis of probable AD was ascertained with the DSM-IV and the NINCDS/ADRDA criteria by a senior researcher (a clinician specialized in geriatric psychiatry/behavioral neurology). For those who had died by the time of the follow up, retrospective data were obtained through a structured telephone interview with a knowledgeable close source focusing on dementia diagnosis. We also carried out the AD8 (an eight-item informant interview) during the same telephone interview (Galvin *et al.*, 2006).

Data obtained through the standardized neuropsychological and neurological evaluation, MMSE, CDR, ADL, MADRS, SRQ and DSM-IV criteria for major depression all gave support to both diagnoses (MCI and AD).

MCI trajectories assessment

Outcomes for this analysis were progression to probable AD (conversion); remaining in the MCI category (stability); and improving to the previous cognitive status (reconversion).

Risk estimation for the conversion to AD

The outcome variable for this analysis was an AD diagnosis. MCI was the main factor. Age, sex, education, family income, major depression, clinical illness, MMSE scores were co-variables.

The study was approved by the Ethics Committee for Research of the Hospital de Clínicas de Porto Alegre. All subjects and/or their proxies signed an informed consent.

Statistical analysis

Baseline demographic and clinical variables from the original sample, from the sample evaluated in this study and from those subjects who did not meet entry criteria for the present study or dropped out at follow-up were compared by analysis of variance (ANOVA) and χ^2 association test.

The cumulative conversion rate was calculated as the number of MCI cases that progressed to probable AD during follow-up divided by the total number of MCI participants. The annual conversion rate was calculated as the quotient of the percentage of MCI subjects who converted to probable AD at follow-up and the mean delay to follow-up. The MCI annual reconversion rate was calculated as the quotient of the percentage of MCI subjects who improved to their previous cognitive status at follow-up and the mean delay to follow-up.

The Cox proportional hazard models and the survival curve were derived from the Kaplan-Meier's method. The univariate Cox proportional hazard model was first used to estimate the relative risks and corresponding 95% CI of developing dementia in relation to baseline MCI diagnosis, age, sex, education, family income, major depression, MMSE scores and minor clinical illness. Baseline MCI diagnosis was entered as a dichotomous variable (yes vs. no). The multivariate Cox proportional hazards model was used to examine the age, education, MMSE and sex adjusted risk of MCI for the outcome of probable AD. All analyses were performed using the Statistical Package for the Social Sciences (SPSS, Version 14.0).

Table 1. Comparison of baseline demographic and clinical variables among the original (N = 345), the present (N = 241) and the drop-out (N = 104) sample.

	ORIGINAL SAMPLE (345)	PRESENT SAMPLE (241)	DROP-OUT SAMPLE (104)	P
Age (mean ± SD)*	70.3 ± 7.2	69.8 ± 6.2	70.8 ± 7.8	0.483
Sex - female (N, %)**	242 (70)	169 (70)	73 (70)	1.00
Education (mean ± SD)*	9.1 ± 5.5	8.9 ± 5.5	9.2 ± 5.5	0.903
Monthly family income (mean ± SD)*	22.5 ± 30.0	22.5 ± 28.3	31.6 ± 2.4	1.00
SRQ*	3.4 ± 2.9	3.7 ± 2.8	3.7 ± 3.0	0.293
MADRS (mean ± SD)*	6.7 ± 6.2	6.4 (5.6)	7.0 ± 6.6	0.627
MMSE (mean ± SD)*	25.3 ± 3.9	25.6 ± 3.1	25.1 ± 4.4	0.447
No minor clinical illness (N, %)**	200 (58)	135 (56)	61 (59)	0.855

* ANOVA analysis of variance; ** χ^2 association test.

MMSE = Mini-Mental State Examination; MADRS = Montgomery-Åsberg Depression Rating Scale; SRQ = self-report questionnaire.

Table 2. Demographic and clinical variables of the three MCI outcomes groups: descriptive analysis

VARIABLE	RECONVERSION (n = 8)	STABILITY (n = 5)	CONVERSION (n = 8)
Age (mean ± SD)	78.0 ± 9.5	75.0 ± 4.3	76.5 ± 2.1
Education (mean ± SD)	4.1 ± 2.7	4.6 ± 3.4	8.9 ± 3.7
Monthly family income (mean ± SD)	23.4 ± 37.9	13.4 ± 0.7	31.5 ± 42.1
Sex - female (N, %)	7 (33)	4 (19)	6 (29)
MMSE (Mini-Mental State Examination)	24.1 ± 1.2	23.8 ± 0.9	24.0 ± 2.2
SRQ (Self-Report Questionnaire)	2.3 ± 1.3	3.3 ± 3.0	0.5 ± 0.7
DSM-IV Major Depression - absent (N, %)	8 (100)	5 (100)	8 (100)
At least 1 minor clinical illness (N, %)	8 (100)	5 (100)	8 (100)

Results

The age of participants ranged from 68 to 96 years (69.8 ± 6.2 , mean SD), educational level ranged from 0 to 35 years of study (8.9 ± 5.5 , mean ± SD) and the monthly family income ranged from 1 to 121 minimum wages (22.5 ± 28.3 , mean ± SD) (1 minimum wage = US\$ 353.00). Of the 241 participants, 169 (70%) were female, 135 (56%) reported no minor clinical illness (Table 1).

In order to ensure similarity, we carried out a comparison of baseline clinical and demographic variables among the original cohort sample (N = 345), the present sample (N = 241) and the group composed of subjects who did not meet entry criteria for the present study or who dropped out at follow-up (N = 104). The groups did not differ (Table 1).

MCI trajectories

Of the 21 MCI subjects, eight (38%) progressed to probable AD, five (24%) remained stable and eight (38%) improved their cognition returning to the previous performance during the mean follow-up of 45.1 months (19–70 months). Table 2 shows

the demographic and clinical data of the three MCI groups. Of the 220 normal participants, three (1.3%) developed dementia, 17 (7.7%) developed MCI and 200 (91%) remained cognitively intact. The dementia cases were all probable AD.

The MCI annual conversion rate to AD was 8.5% (CI 95% 3.9–16.1) and the MCI annual reconversion rate was 8.5% (CI 95% 3.9–16.1). The annual conversion rate to AD for participants who did not have cognitive impairment was 1.8% (CI 95% 0.1–8.8).

MCI as risk factor for AD

Age, sex, education, family income, major depression and minor clinical illness did not influence the risk of progressing to Alzheimer's disease in the univariate Cox regression model (Table 3). Lower baseline MMSE scores and MCI were risk factors for AD in the univariate model (HR = 1.10, $p = 0.006$, and HR = 23.3, $p = 0.004$, respectively).

The MCI group was associated with significant risk for AD compared to the group that was not cognitively impaired (HR = 49.83; $p = 0.004$) after the adjustment for age, education, sex and MMSE

Table 3. Cox regression – univariate analysis: variables MCI diagnosis, MMSE, age, sex, education, monthly family income, Major Depression and presence of minor clinical illness for the outcome progression to probable AD


PREDICTORS	B	HR (95% CI)	P VALUE
MCI diagnosis *	3.15	23.32 (2.8–194.3)	0.004
Age	0.07	1.07 (1.0–1.2)	0.270
Sex**	–0.25	0.78 (0.3–2.1)	0.630
Education	–0.02	0.98 (0.9–1.1)	0.616
MMSE	0.10	1.10 (1.0–1.2)	0.006
Family income (monthly US\$)	0.00	1.01(1.0–1.1)	0.938
DSM-IV Major Depression***	3.16	2.36 (0.0–4.6)	0.712
At least 1 minor clinical illness	–3.14	0.04 (0.0–1.86)	0.726

* MCI diagnosis (**yes** is the reference).

** Female sex is the reference.

*** Presence of Major Depression is the reference.

MCI = mild cognitive impairment; MMSE = Mini-Mental State Examination; AD = Alzheimer's disease.

**Figure 1.** Survival rate for the outcome of Alzheimer's disease

(Table 4). Figure 1 illustrates the survival rate for the outcome of AD according to MCI diagnosis, showing higher risk of conversion of MCI subjects.

Discussion

The present investigation was derived from an ongoing longitudinal evaluation of community-living elderly individuals in southern Brazil – the PALA study. In this region of Brazil, *pala* in Portuguese also designates part of the typical garment worn by gauchos, a cape. The aims of

this study were to evaluate the trajectory of MCI and to estimate the MCI risk for the development of AD in comparison with healthy subjects. We used MCI criteria that emphasize episodic memory impairment (MCI of Alzheimer type) that could be more associated with development of AD. We found heterogeneity of MCI outcomes, with the same cumulative proportion of conversion to AD and reconversion to normal cognition (38%) and lower cumulative proportion of stability (24%). The majority of individuals from this study did not convert (62%), which is similar to findings in other investigations (Larrieu *et al.*, 2002; Matthews *et al.*,

Table 4. Cox regression – multivariate analysis: MCI diagnosis as main factor, variables age, sex, education, and MMSE as co-variables for the outcome progression to probable AD

PREDICTORS	B	HR (95% CI)	P VALUE
MCI diagnosis*	3.91	49.83 (3.6–698.1)	0.004
MMSE	–0.22	0.80 (0.59–1.092)	0.163
Age	0.04	1.04 (0.91–1.2)	0.579
Sex	–0.18	0.84 (0.15–4.74)	0.843
Education	0.16	1.17 (0.98–1.40)	0.089

* MCI diagnosis (yes is the reference).

HR = hazard rate; CI = confidence interval; MCI = mild cognitive impairment; MMSE = Mini-Mental State Examination.

2008; Mitchel and Shiri-Feshki, 2009; Ganguli *et al.*, 2011). The similarity between conversion and reconversion to normal rates could be explained by the sample's characteristics. The higher proportion of no conversion could be attributed to the community-based sample that has been already related to lower conversion rates (Mitchel and Shiri-Feshki, 2009; Ganguli *et al.*, 2011). Despite the utilized MCI criteria which emphasize that memory impairment is associated with higher conversion to AD (Larrieu *et al.*, 2002; Petersen *et al.*, 1997; Sarazin *et al.*, 2007; Ganguli *et al.*, 2011), these criteria are classified as single cognitive domain type and have been associated with higher rates of reconversion (Manly *et al.*, 2008; Ganguli *et al.*, 2011). Previous studies have shown that 6%–53% of the MCI cohort could revert back to normal after initially being diagnosed (Larrieu *et al.*, 2002; Matthews *et al.*, 2008; Mitchel and Shiri-Feshki, 2009; Ganguli *et al.*, 2011). Participants from our study who improved and returned to their previous cognitive status could present some degree of visual or hearing impairment, depressive symptoms and use of medications as the cause of the memory deficit. Additionally, intra-individual variability could explain these results.

Regardless of heterogeneity of the outcomes, MCI participants from this cohort showed significantly higher risk of developing probable AD as compared to those who were cognitively intact (HR = 49.83), even after the adjustment for age, education, MMSE and sex. The risk range in previous studies varied from 2.77 to 63.49 (Bruscoli and Lovestone, 2004; Ishikawa *et al.*, 2006; Dickerson *et al.*, 2007; Palmer *et al.*, 2008; Matthews *et al.*, 2008; Mitchell and Shiri-Feshki, 2009; Ganguli *et al.*, 2011) and therefore the observed risk can be considered high. The chance of developing AD during six years of follow-up of an elderly subject with MCI is 49 times higher than for a cognitively intact participant. Given that

the application of MCI of Alzheimer type criteria increases the probability of identifying individuals during the prodromal stages of AD, one might expect higher risk estimates because the emphasis on long-term episodic memory impairment seems to add predictive value for these criteria, since AD neuropathological changes can be early present in areas critical for this type of memory such as mesial temporal regions (Dubois and Albert, 2004). This finding exemplifies the importance of the new MCI approach. However, if all MCI identified were prodromic AD, the estimated risk would be even higher. To increase criteria specificity, the inclusion of other measures seems to be essential. These criteria are in conformity with the newly research criteria for the diagnosis of AD which require an episodic memory deficit as the core clinical criterion (criterion A) and the presence of at least one biological marker of the disease, either by structural imaging (criterion B), CSF (criterion C), molecular imaging (criterion D) or dominant mutation within the immediate family (criterion E) to establish a positive diagnosis (Dubois *et al.*, 2007).

Because age, sex, education, income, baseline MMSE scores, and other clinical variables might affect the progression to probable AD, we performed Cox regressions with all these variables. MCI diagnosis and MMSE scores were kept in the final model in the univariate design. However, the well-established relation of age, sex and education with AD (Solfrizzi *et al.*, 2004; Chaves *et al.*, 2009b) demanded their inclusion in the Cox multivariate model. The higher multivariate hazard of the MCI diagnosis could be explained by some interaction with these other variables reinforcing the association with the progression to AD. This finding suggests that education separately, besides age and sex, did not influence progression to probable AD among individuals supposedly in their earliest stages of the disease. Furthermore, among older individuals from less economically advantaged regions, with average lower levels of education than people from developed countries, their education did not affect the trajectory from MCI to AD. Lower educational levels found in developing countries could be a confounder for the MCI evaluation. Overestimation of MCI rates and lower MCI conversion rates to dementia could be observed because of the higher false positive rates produced by the lower educational level. However, the current findings rejected this hypothesis. In a previous investigation (Chaves *et al.*, 2009a), we observed a similar MCI incidence rate to those found in the majority of the studies carried out in developed countries (Kukull *et al.*, 2002; Larrieu *et al.*, 2002; Matthews *et al.*, 2008; Ganguli *et al.*, 2011).

Some limitations of our study should be considered: the proportion and conversion rates were based on relatively few MCI participants given the community origin of the sample. However, this number was sufficient to allow the estimation of risk. As already mentioned, one problem of detecting cases at time intervals is the underestimation of the outcome (Solfrizzi *et al.*, 2004). In the case of MCI, subjects could present this condition during the interval period and at interviews when they have already converted to dementia. Another limitation was the drop-out rate (around 30%) during the follow-up, which prevents estimation of the impact of this loss on the results. However, by comparing the baseline clinical and demographic variables among the original cohort sample, the sample evaluated in this study and the drop-out group we minimized this limitation because no difference was observed.

The strengths of the study include the use of a population-based sample evaluated comprehensively; the length of follow-up; the use of internationally accepted instruments validated locally; and the diagnosis according to international and recent criteria together providing representative information about older residents living in urban areas in Brazil.

Finally, because we are following this elderly sample in our community, we can help plan for the future through evaluation of additional refinements to MCI measures and the validation of the research criteria for AD in Brazil.

Conflict of interest

None.

Description of authors' roles

Claudia Godinho and Marcia Chaves formulated the research question, designed the study, and wrote the paper. Ana Luiza Camozzato analyzed the data and helped write the paper. Diego Onyszko collected part of the data and helped with the references.

Acknowledgment

This study was supported by grants from CNPq (350027/1995-1 and 306458/2004-7).

References

Artero, S. *et al.* (2008). Risk profiles for mild cognitive impairment and progression to dementia are gender specific. *Journal of Neurology, Neurosurgery and Psychiatry*, 79, 979–984.

- Bozoki, A., Giordani, B., Heidebrink, J. L., Berent, S. and Foster, N. L.** (2001). Mild cognitive impairments predict dementia in non demented elderly patients with memory loss. *Archives of Neurology*, 58, 411–416.
- Bruscoli, M. and Lovestone, S.** (2004). Is MCI really just early dementia? A systematic review of conversion studies. *International Psychogeriatrics*, 16, 129–140.
- Chaves, M. L., Camozzato, A. L., Godinho, C., Piazenski, I. and Kaye, J.** (2009a). Incidence of mild cognitive impairment and Alzheimer disease in southern Brazil. *Journal of Geriatric Psychiatry and Neurology*, 22, 181–187.
- Chaves, M. L., Camozzato, A. L., Eizirik, C. L and Kaye, J.** (2009b). Predictors of normal and successful aging among urban-dwelling elderly Brazilians. *Journal of Gerontology: Psychological Sciences*, 64B, 597–602.
- Das, S. K. *et al.*** (2007). An epidemiologic study of mild cognitive impairment in Kolkata, India. *Neurology*, 68, 2019–2026.
- Devanand, D. P. *et al.*** (2007). Hippocampal and entorhinal atrophy in mild cognitive impairment prediction of Alzheimer disease. *Neurology*, 68, 828–836.
- Dickerson, B. C. *et al.*** (2007). Clinical prediction of Alzheimer disease dementia across the spectrum of mild cognitive impairment. *Archives of General Psychiatry*, 64, 1443–1450.
- Dubois, B. and Albert, M. L.** (2004). Amnesic MCI or prodromal Alzheimer's disease? *Lancet Neurology*, 3, 246–248.
- Dubois, B. *et al.*** (2007). Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. *Lancet Neurology*, 6, 734–746.
- Ferri, C. P. *et al.*** (2005). Alzheimer's Disease International global prevalence of dementia: a Delphi consensus study. *Lancet*, 366, 2112–2117.
- Galvin, J., Roe, C., Xiong, C. and Morris, J. C.** (2006). Validity and reliability of the AD8 informant interview in dementia. *Neurology*, 67, 1942–1948.
- Ganguli, M. *et al.*** (2011). Outcomes of mild cognitive impairment by definition. a population study. *Archives of Neurology*, 68, 761–767.
- Hansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K. and Minthon, L.** (2006). Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. *Lancet Neurology*, 5, 228–234.
- Huang, J. *et al.*** (2005). Progression of Mild Cognitive Impairment to Alzheimer's or vascular dementia versus normative aging among elderly Chinese. *Current Alzheimer Research*, 2, 571–578.
- Ishikawa, T., Ikeda, M., Matsumoto, N., Shigenobu, K., Brayne, C. and Hirotsuka, T. H.** (2006). A longitudinal study regarding conversion from mild memory impairment to dementia in a Japanese community. *International Journal of Geriatric Psychiatry*, 21, 134–139.
- Jack, C. R. *et al.*** (2004). Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. *Neurology*, 62, 591–600.
- Kukull, W. A. *et al.*** (2002). Dementia and Alzheimer disease incidence. *Archives of Neurology*, 59, 1737–1746.
- Larrieu, S. *et al.*** (2002). Incidence and outcome of mild cognitive impairment in a population-based prospective cohort. *Neurology*, 59, 1594–1595.

- Manly, J. J., Tang, M. X., Schupf, N., Stern, Y., Vonsattel, J. P. and Mayeux, R.** (2008). Frequency and course of mild cognitive impairment in a multi-ethnic community. *Annals of Neurology*, 63, 494–506.
- Matthews, F. E. et al.** (2008). Medical Research Council Cognitive Function and Ageing Study. Two-year progression from mild cognitive impairment to dementia: to what extent do different definitions agree? *Journal of the American Geriatrics Society*, 56, 1424–1433.
- Mitchell, A. J. and Shiri-Feshki, M.** (2009). Rate of progression of mild cognitive impairment to dementia: meta-analysis of 41 robust inception cohort studies. *Acta Psychiatrica Scandinavica*, 119, 256–265.
- Palmer, K., Wang, H-X., Backman, L., Winblad, B. and Fratiglioni, L.** (2002). Differential evolution in non demented older persons: results from the Kungsholmen Project. *American Journal of Psychiatry*, 159, 436–442.
- Palmer, K., Backman, L., Winblad, B. and Fratiglioni, L.** (2008). Mild cognitive impairment in the general population: occurrence and progression to Alzheimer disease. *American Journal of Geriatric Psychiatry*, 16, 603–611.
- Petersen, R., Smith, G., Waring, S., Ivnik, R., Kokmen, E. and Tangelos, E.** (1997). Aging, memory, and mild cognitive impairment. *International Psychogeriatrics*, 9, 65–69.
- Petersen, R. C. et al.** (2001). Current concepts in mild cognitive impairment. *Archives of Neurology*, 58, 1985–1992.
- Sarazin, M. et al.** (2007). Amnesic syndrome of the medial temporal type identifies prodromal AD: a longitudinal study. *Neurology*, 69, 1859–1867.
- Schmidtke, K. and Hermeneit, S.** (2008). High rate of conversion to Alzheimer's disease in a cohort of amnesic MCI patients. *International Psychogeriatrics*, 20, 96–108.
- Solfrizzi, V., Panza, F. and Colacicco, A. M.** (2004). Vascular risk factors, incidence of MCI, and rates of progression to dementia. *Neurology*, 63, 1882–1891.
- Winblad, B. et al.** (2004). Mild cognitive impairment beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. *Journal of Internal Medicine*, 256, 240–246.
- Wolf, H. et al.** (1998). The prognosis of mild cognitive impairment in the elderly. *Journal of Neural Transmission Supplement*, 54, 31–50.